Skip to main content
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. — Investor Relations & Filings

Ticker · OVID ISIN · US6904691010 LEI · 549300H36NUI4L6U8F17 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2025-12-10 Director's Dealing
Country US United States of America
Listing US OVID

About Ovid Therapeutics Inc.

https://ovidrx.com/

Ovid Therapeutics Inc. is a biopharmaceutical company that develops targeted small molecule therapies for neurological conditions. The company's primary focus is on conquering epilepsies and other brain disorders by creating treatments that aim to reduce seizures and offer improved safety and tolerability. Ovid's scientific approach involves pioneering compounds with unique or potentially best-in-class mechanisms of action to address significant unmet medical needs. The company's mission is to develop medicines that improve the lives of patients and families affected by these conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-12-10 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-12-10 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a leadership succession announcement (appointment of a new CEO and changes in executive roles), business updates, and a reference to third quarter 2025 financial results announced via a press release (Exhibit 99.1). The document does not contain full financial statements or detailed financial analysis itself but rather announces these events and references a press release. The document also includes employment agreement summaries and severance terms for executives, which are typical disclosures in a Form 8-K. Given the nature of the content and the form type, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories such as Annual Report, Earnings Release, or Management Reports. The document is not a full financial report, not a proxy statement, nor a call transcript, and it is not a simple announcement of a report publication but a substantive current report filing with multiple disclosures.
2025-11-12 English
DEF 14A
Proxy Solicitation & Information Statement
2025-11-07 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a Preliminary Proxy Statement for a Special Meeting of Stockholders of Ovid Therapeutics Inc. It includes detailed information about proposals to be voted on, voting procedures, record dates, and meeting logistics. The document is not a financial report, earnings release, or management discussion but is clearly a solicitation of shareholder votes and information related to a shareholder meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains the full proxy statement text, not just an announcement or a brief notice, so it is not an RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2025-10-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.